| Autor: |
Wunker C; Institute of Medical Science, University of Toronto; 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital., Piorkowska K; The Wilfred and Joyce Posluns Centre for Image-Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children., Keunen B; The Wilfred and Joyce Posluns Centre for Image-Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children., Babichev Y; 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital., Wong SM; The Wilfred and Joyce Posluns Centre for Image-Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children; Institute of Biomedical Engineering, University of Toronto., Regenold M; Leslie Dan Faculty of Pharmacy, University of Toronto., Dunne M; Leslie Dan Faculty of Pharmacy, University of Toronto., Nomikos J; Institute of Medical Science, University of Toronto; 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital., Siddiqui M; Departments of Radiology and Clinical Neurosciences, University of Calgary., Pichardo S; Departments of Radiology and Clinical Neurosciences, University of Calgary., Foltz W; Department of Radiation Oncology, University of Toronto., Waspe AC; The Wilfred and Joyce Posluns Centre for Image-Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children; Department of Medical Imaging, University of Toronto., Gerstle JT; The Wilfred and Joyce Posluns Centre for Image-Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children; Department of Pediatric Surgery, University of Toronto., Gladdy RA; Institute of Medical Science, University of Toronto; 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Department of Surgery, University of Toronto; gladdy@lunenfeld.ca. |
| Abstrakt: |
Magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) is an established method for producing localized hyperthermia. Given the real-time imaging and acoustic energy modulation, this modality enables precise temperature control within a defined area. Many thermal applications are being explored with this noninvasive, nonionizing technology, such as hyperthermia generation, to release drugs from thermosensitive liposomal carriers. These drugs can include chemotherapies such as doxorubicin, for which targeted release is desired due to the dose-limiting systemic side effects, namely cardiotoxicity. Doxorubicin is a mainstay for treating a variety of malignant tumors and is commonly used in relapsed or recurrent rhabdomyosarcoma (RMS). RMS is the most common solid soft tissue extracranial tumor in children and young adults. Despite aggressive, multimodal therapy, RMS survival rates have remained the same for the past 30 years. To explore a solution for addressing this unmet need, an experimental protocol was developed to evaluate the release of thermosensitive liposomal doxorubicin (TLD) in an immunocompetent, syngeneic RMS mouse model using MRgHIFU as the source of hyperthermia for drug release. |
